Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Top Cited Papers
- 1 March 2018
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 175 (3), 225-231
- https://doi.org/10.1176/appi.ajp.2017.17030325
Abstract
Objective: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. Method: In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1: 1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S). Results: After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms (PANSS: treatment difference=21.4, 95% CI=-2.5,-0.2) and were more likely to have been rated as improved (CGI-I: treatment difference=-0.5, 95% CI=-0.8, -0.1) and as not severely unwell (CGI-S: treatment difference=-0.3, 95% CI=-0.5, 0.0) by the treating clinician. Patients who received CBD also showed greater improvements that fell short of statistical significance in cognitive performance (BACS: treatment difference=1.31, 95% CI=-0.10, 2.72) and in overall functioning (GAF: treatment difference=3.0, 95% CI=-0.4, 6.4). CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups. Conclusions: These findings suggest that CBD has beneficial effects in patients with schizophrenia. AsCBD's effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.This publication has 18 references indexed in Scilit:
- Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disordersPhilosophical Transactions B, 2012
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairmentJournal of Psychopharmacology, 2012
- A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational InvestigationCurrent Pharmaceutical Design, 2012
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agentsMolecular Psychiatry, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary reportJournal of Psychopharmacology, 2010
- Review: The biological basis of antipsychotic response in schizophreniaJournal of Psychopharmacology, 2009
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and PsychopathologyNeuropsychopharmacology, 2009
- Cannabidiol for the treatment of psychosis in Parkinson’s diseaseJournal of Psychopharmacology, 2008
- Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugsMolecular Psychiatry, 2004